- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | UCB's Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults | ||
| Mi | Is the new Health and Social Care Select Committee a battleground or consensus opportunity? | ||
| Mi | Bringing more effective storytelling to medical publications | ||
| Di | Biogen/Eisai's Alzheimer's drug lecanemab receives CHMP recommendation | ||
| Di | The potential of generative AI and its practical application in the world of promotional medical communications | ||
| Di | Impending ESG regulations present communications opportunity for pharma | ||
| Mo | Merck gains rights to LaNova's PD-1/VEGF bispecific antibody in deal worth over $3.2bn | ||
| Mo | European Medicines Group appoints Rippon Ubhi as chair | ||
| Mo | Creative strategy in medical communications | ||
| Fr | GSK and Vesalius partner on new Parkinson's treatments in deal worth $650m | ||
| Fr | ICR researchers identify potential treatment approach for acute myeloid leukaemia | ||
| Fr | Cutting through the maze of obstacles to liberate patient pathways | ||
| 14.11. | Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn | ||
| 14.11. | Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type | ||
| 14.11. | Is Gen AI ready for life sciences? | ||
| 13.11. | Roche and Flare Therapeutics enter oncology partnership worth over $1.8bn | ||
| 13.11. | AstraZeneca/Merck's Koselugo shows promise in adults with neurofibromatosis type 1 | ||
| 13.11. | J&J's nipocalimab granted FDA breakthrough designation for Sjögren's disease | ||
| 12.11. | Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study | ||
| 12.11. | J&J submits EU and US applications for subcutaneous Darzalex in smouldering multiple myeloma | ||
| 12.11. | Ogilvy appoints Mario Muredda as global chief executive officer of Ogilvy Health | ||
| 11.11. | FDA approves Autolus' Aucatzyl to treat acute lymphoblastic leukaemia | ||
| 11.11. | Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu | ||
| 11.11. | AstraZeneca/Amgen's Tezspire shows promise in phase 3 CRSwNP trial | ||
| 08.11. | WHO announces priority endemic pathogens for urgent vaccine development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
